North Star Asset Management Inc. Buys 17,508 Shares of Edwards Lifesciences Co. (NYSE:EW)

North Star Asset Management Inc. boosted its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 98.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 35,271 shares of the medical research company's stock after purchasing an additional 17,508 shares during the period. North Star Asset Management Inc.'s holdings in Edwards Lifesciences were worth $2,611,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in Edwards Lifesciences in the fourth quarter valued at $1,006,000. Vega Investment Solutions acquired a new position in Edwards Lifesciences in the fourth quarter valued at $27,000. Vise Technologies Inc. increased its stake in Edwards Lifesciences by 48.5% in the fourth quarter. Vise Technologies Inc. now owns 5,209 shares of the medical research company's stock valued at $386,000 after purchasing an additional 1,702 shares during the period. Orion Capital Management LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at $113,000. Finally, White Knight Strategic Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at $303,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 1.4%

Shares of EW traded up $1.06 on Thursday, hitting $77.72. 4,077,349 shares of the stock traded hands, compared to its average volume of 5,155,216. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $45.59 billion, a P/E ratio of 11.15, a P/E/G ratio of 4.82 and a beta of 1.12. The stock's 50 day moving average is $73.09 and its two-hundred day moving average is $72.25. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the business posted $0.66 earnings per share. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of recent research reports. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Truist Financial dropped their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Canaccord Genuity Group boosted their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. Finally, Piper Sandler boosted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $80.20.

Insider Activity

In related news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the sale, the vice president now owns 33,496 shares of the company's stock, valued at $2,514,879.68. The trade was a 4.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,692 shares of company stock valued at $4,822,074. Company insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.